The global conjunctivitis treatment market revenue was around US$ 4.9 billion in 2021 and is estimated to reach US$ 6.9 billion by 2031, growing at a compound annual growth rate (CAGR) of 3.8% during the forecast period from 2022 to 2031.
Conjunctivitis is an inflammation of the membrane that covers the eye's surface. It could be brought on by eye discomfort or an infection. The conjunctiva is a membrane that covers the inside of the eyelids and the surface of the eyeball. Allergens can irritate the conjunctiva, especially during the hay fever season.
Factors Influencing Market Growth
Rise in the number of people suffering from allergic conjunctivitis around the world and the rising demand for healthcare services. Such, these factors boost the market growth.
Several major market participants are concentrating on R&D operations to produce medications for allergic conjunctivitis as the patient population grows. Thus, it is anticipated to fuel the market expansion.
The increasing interest of manufacturers and developers in creating conjunctivitis treatments and introducing new products propels the market growth.
Expensive financial inputs are required to produce the products. Thus, it is predicted to hamper the market growth.
Study of the COVID-19 Pandemic
The COVID-19 pandemic had a negative impact on the market. There were three main ways that COVID-19 influenced the economy: directly by impacting demand and supply, indirectly by disrupting distribution networks, and financially by affecting businesses and financial markets. Due to the lockdown enacted by the government, many nations, including China, India, UAE, Saudi Arabia, Egypt, and others, experienced issues with the transfer of pharmaceuticals from one location to another. The supply of raw materials needed to make medicine formulations was one of the biggest obstacles because of disruption in transportation.
Regional Insights
North America dominated the market. Due to its established healthcare infrastructure, improvements in conjunctivitis treatment, and the presence of major players boost the market expansion in this region.
However, Asia Pacific is predicted to experience tremendous growth due to the region's higher rate of product introductions, higher healthcare costs, and large population base.
Leading Competitors
The leading competitors in the global conjunctivitis treatment market are:
Jawa Pharmaceuticals Pvt. Ltd
AFT Pharmaceuticals
Abbvie Inc
Indoco Remedies Ltd
Cipla, Inc
Spectra Vision Care Pvt Ltd
Jabs Biotech Pvt Ltd
Grevis Pharmaceutical Private Limited
Sun Pharmaceuticals Industries Ltd
Ocular Therapeutics
Teva Pharmaceutical Industries Ltd
Johnson & Johnson Services Inc
Novartis AG
Bausch Health Companies Inc
Ajanta Pharma Limited
Santen Pharmaceuticals Co. Ltd
Alembic Pharmaceuticals Ltd
Others
Segmentation Analysis
The global conjunctivitis treatment market segmentation focuses on Drug Class, Disease Type, Distribution Channel, and Region.
Segmentation based on Drug Class
Antibiotics
Antiviral
Anti-allergic
Artificial Tears
Segmentation based on Disease Type
Allergic Conjunctivitis
o Seasonal Allergic Conjunctivitis
o Perennial Allergic Conjunctivitis
Bacterial Conjunctivitis
Viral Conjunctivitis
Segmentation based on Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Segmentation based on Region
North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America
